ASCO: Results of DREAMM-6

DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Abstract No : 8502

Abstract Type : Oral Abstract Session

Indication : Multiple Myeloma

Intervention : Belantamab mafodotin

Company : GlaxoSmithKline

Technology : BCMA Inhibitor


As of February 6, 2020, 52 patients were enrolled: 6 patients were enrolled at 2.5 mg/kg single dose and 7 at 3.4 mg/kg single dosing in Part 1, and 45 patients in Part 2. No dose-limiting toxicities were observed. Corneal events (including keratopathy, blurred vision, and dry eye) and thrombocytopenia were the most frequently reported AEs and were clinically manageable.


In DREAMM-6, preliminary data demonstrate that the combination of belantamab mafodotin and BorDex has an acceptable safety profile, with no new safety signals identified. Funding: GlaxoSmithKline (207497). Drug linker technology licensed from Seattle Genetics; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.


Huge potential for belantamab mafodotin as combination therapy in patients with earlier stages of multiple myeloma agent owing to its promising response data and acceptable safety profile